Oliver Lagore Vanvalin Investment Group’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $19.7K | Buy |
+508
| New | +$19.7K | 0.01% | 340 |
|
|
2024
Q4 | $17.5K | Sell |
518
-53
| -9% | -$1.79K | ﹤0.01% | 379 |
|
|
2024
Q3 | $23.3K | Sell |
571
-85
| -13% | -$3.48K | 0.01% | 330 |
|
|
2024
Q2 | $25.3K | Sell |
656
-51
| -7% | -$1.96K | 0.01% | 311 |
|
|
2024
Q1 | $30.3K | Sell |
707
-5
| -0.7% | -$214 | 0.01% | 290 |
|
|
2023
Q4 | $26.4K | Buy |
712
+45
| +7% | +$1.67K | 0.01% | 285 |
|
|
2023
Q3 | $24.2K | Buy |
667
+89
| +15% | +$3.23K | 0.01% | 325 |
|
|
2023
Q2 | $20.6K | Hold |
578
| – | – | 0.01% | 365 |
|
|
2023
Q1 | $20.6K | Buy |
578
+1
| +0.2% | +$36 | 0.01% | 278 |
|
|
2022
Q4 | $20.3K | Buy |
577
+324
| +128% | +$11.4K | 0.01% | 271 |
|
|
2022
Q3 | $7K | Buy |
253
+79
| +45% | +$2.19K | ﹤0.01% | 386 |
|
|
2022
Q2 | $9K | Buy |
174
+14
| +9% | +$724 | 0.01% | 347 |
|
|
2022
Q1 | $9K | Buy |
+160
| New | +$9K | 0.01% | 345 |
|